(Q33738435)

English

Wild-type MIC distributions, epidemiological cutoff values and species-specific clinical breakpoints for fluconazole and Candida: Time for harmonization of CLSI and EUCAST broth microdilution methods

scientific article published on November 2, 2010

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Wild-type MIC distributions, epidemiological cutoff values and species-specific clinical breakpoints for fluconazole and Candida: time for harmonization of CLSI and EUCAST broth microdilution methods (English)

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Wild-type MIC distributions, epidemiological cutoff values and species-specific clinical breakpoints for fluconazole and Candida: Time for harmonization of CLSI and EUCAST broth microdilution methods (English)

1 reference

10.1016/J.DRUP.2010.09.002

https://api.crossref.org/works/10.1016/J.DRUP.2010.09.002

20 August 2024

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Michael A. Pfaller

1

object named as

M A Pfaller

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

2

object named as

D. Andes

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21050800

20 August 2024

Daniel J. Diekema

3

object named as

D. J. Diekema

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21050800

20 August 2024

author name string

CLSI Subcommittee for Antifungal Susceptibility Testing

6

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

A. Espinel-Ingroff

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21050800

20 August 2024

D. Sheehan

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21050800

20 August 2024

language of work or name

1 reference

National Center for Biotechnology Information

PubMed publication ID

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=21050800

20 August 2024

publication date

2 November 2010

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

full work available at URL

https://api.elsevier.com/content/article/PII:S1368764610000488?httpAccept=text/xml

1 reference

10.1016/J.DRUP.2010.09.002

https://api.crossref.org/works/10.1016/J.DRUP.2010.09.002

20 August 2024

https://api.elsevier.com/content/article/PII:S1368764610000488?httpAccept=text/plain

1 reference

10.1016/J.DRUP.2010.09.002

https://api.crossref.org/works/10.1016/J.DRUP.2010.09.002

20 August 2024

Drug Resistance Updates

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

13

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

6

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

180-195

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Candida glabrata fungemia in transplant patients receiving voriconazole after fluconazole

1

1 reference

10.1016/J.DRUP.2010.09.002

https://api.crossref.org/works/10.1016/J.DRUP.2010.09.002

20 August 2024

In vivo pharmacodynamics of antifungal drugs in treatment of candidiasis

2

1 reference

10.1016/J.DRUP.2010.09.002

https://api.crossref.org/works/10.1016/J.DRUP.2010.09.002

20 August 2024

Pharmacokinetics and pharmacodynamics of antifungals

3

1 reference

10.1016/J.DRUP.2010.09.002

https://api.crossref.org/works/10.1016/J.DRUP.2010.09.002

20 August 2024

Impact of antimicrobial dosing regimen on evolution of drug resistance in vivo: fluconazole and Candida albicans

5

1 reference

10.1016/J.DRUP.2010.09.002

https://api.crossref.org/works/10.1016/J.DRUP.2010.09.002

20 August 2024

In vivo fluconazole pharmacodynamics and resistance development in a previously susceptible Candida albicans population examined by microbiologic and transcriptional profiling

6

1 reference

10.1016/J.DRUP.2010.09.002

https://api.crossref.org/works/10.1016/J.DRUP.2010.09.002

20 August 2024

Candidemia in a tertiary care cancer center: in vitro susceptibility and its association with outcome of initial antifungal therapy

7

1 reference

10.1016/J.DRUP.2010.09.002

https://api.crossref.org/works/10.1016/J.DRUP.2010.09.002

20 August 2024

Breakpoints for susceptibility testing should not divide wild-type distributions of important target species

8

1 reference

10.1016/J.DRUP.2010.09.002

https://api.crossref.org/works/10.1016/J.DRUP.2010.09.002

20 August 2024

Correlation of in vitro fluconazole susceptibility with clinical outcome for severely ill patients with oropharyngeal candidiasis.

9

1 reference

10.1016/J.DRUP.2010.09.002

https://api.crossref.org/works/10.1016/J.DRUP.2010.09.002

20 August 2024

Comparison of visual and spectrophotometric methods of broth microdilution MIC end point determination and evaluation of a sterol quantitation method for in vitro susceptibility testing of fluconazole and itraconazole against trailing and nontrailin

10

1 reference

10.1016/J.DRUP.2010.09.002

https://api.crossref.org/works/10.1016/J.DRUP.2010.09.002

20 August 2024

Utility of real-time antifungal susceptibility testing for fluconazole in the treatment of candidemia

11

1 reference

10.1016/J.DRUP.2010.09.002

https://api.crossref.org/works/10.1016/J.DRUP.2010.09.002

20 August 2024

Association of fluconazole pharmacodynamics with mortality in patients with candidemia

12

1 reference

10.1016/J.DRUP.2010.09.002

https://api.crossref.org/works/10.1016/J.DRUP.2010.09.002

20 August 2024

Mechanism of increased fluconazole resistance in Candida glabrata during prophylaxis

13

1 reference

10.1016/J.DRUP.2010.09.002

https://api.crossref.org/works/10.1016/J.DRUP.2010.09.002

20 August 2024

Rapid acquisition of stable azole resistance by Candida glabrata isolates obtained before the clinical introduction of fluconazole

14

1 reference

10.1016/J.DRUP.2010.09.002

https://api.crossref.org/works/10.1016/J.DRUP.2010.09.002

20 August 2024

Mechanisms of azole resistance in petite mutants of Candida glabrata

15

1 reference

10.1016/J.DRUP.2010.09.002

https://api.crossref.org/works/10.1016/J.DRUP.2010.09.002

20 August 2024

Application of real-time quantitative PCR to molecular analysis of Candida albicans strains exhibiting reduced susceptibility to azoles

16

1 reference

10.1016/J.DRUP.2010.09.002

https://api.crossref.org/works/10.1016/J.DRUP.2010.09.002

20 August 2024

Fluconazole MIC and the fluconazole dose/MIC ratio correlate with therapeutic response among patients with candidemia.

17

1 reference

10.1016/J.DRUP.2010.09.002

https://api.crossref.org/works/10.1016/J.DRUP.2010.09.002

20 August 2024

To test or not to test: a cost minimization analysis of susceptibility testing for patients with documented Candida glabrata fungemias.

22

1 reference

10.1016/J.DRUP.2010.09.002

https://api.crossref.org/works/10.1016/J.DRUP.2010.09.002

20 August 2024

Comparative evaluation of NCCLS M27-A and EUCAST broth microdilution procedures for antifungal susceptibility testing of candida species

23

1 reference

10.1016/J.DRUP.2010.09.002

https://api.crossref.org/works/10.1016/J.DRUP.2010.09.002

20 August 2024

Data mining validation of fluconazole breakpoints established by the European Committee on Antimicrobial Susceptibility Testing

24

1 reference

10.1016/J.DRUP.2010.09.002

https://api.crossref.org/works/10.1016/J.DRUP.2010.09.002

20 August 2024

Evaluation by data mining techniques of fluconazole breakpoints established by the Clinical and Laboratory Standards Institute (CLSI) and comparison with those of the European Committee on Antimicrobial Susceptibility Testing (EUCAST)

25

1 reference

10.1016/J.DRUP.2010.09.002

https://api.crossref.org/works/10.1016/J.DRUP.2010.09.002

20 August 2024

International and multicenter comparison of EUCAST and CLSI M27-A2 broth microdilution methods for testing susceptibilities of Candida spp. to fluconazole, itraconazole, posaconazole, and voriconazole

26

1 reference

10.1016/J.DRUP.2010.09.002

https://api.crossref.org/works/10.1016/J.DRUP.2010.09.002

20 August 2024

Gain of function mutations in CgPDR1 of Candida glabrata not only mediate antifungal resistance but also enhance virulence

27

1 reference

10.1016/J.DRUP.2010.09.002

https://api.crossref.org/works/10.1016/J.DRUP.2010.09.002

20 August 2024

Multiple molecular mechanisms contribute to a stepwise development of fluconazole resistance in clinical Candida albicans strains.

28

1 reference

10.1016/J.DRUP.2010.09.002

https://api.crossref.org/works/10.1016/J.DRUP.2010.09.002

20 August 2024

Genetic basis for differential activities of fluconazole and voriconazole against Candida krusei

29

1 reference

10.1016/J.DRUP.2010.09.002

https://api.crossref.org/works/10.1016/J.DRUP.2010.09.002

20 August 2024

Inadequacy of fluconazole dosing in patients with candidemia based on Infectious Diseases Society of America (IDSA) guidelines

30

1 reference

10.1016/J.DRUP.2010.09.002

https://api.crossref.org/works/10.1016/J.DRUP.2010.09.002

20 August 2024

Fluconazole. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial and systemic mycoses

32

1 reference

10.1016/J.DRUP.2010.09.002

https://api.crossref.org/works/10.1016/J.DRUP.2010.09.002

20 August 2024

Fluconazole resistance mechanisms inCandida krusei: The contribution of efflux-pumps

33

1 reference

10.1016/J.DRUP.2010.09.002

https://api.crossref.org/works/10.1016/J.DRUP.2010.09.002

20 August 2024

Real-time antifungal susceptibility screening aids management of invasive yeast infections in immunocompromised patients

34

1 reference

10.1016/J.DRUP.2010.09.002

https://api.crossref.org/works/10.1016/J.DRUP.2010.09.002

20 August 2024

Therapeutic drug monitoring for triazoles

35

1 reference

10.1016/J.DRUP.2010.09.002

https://api.crossref.org/works/10.1016/J.DRUP.2010.09.002

20 August 2024

European harmonization of MIC breakpoints for antimicrobial susceptibility testing of bacteria

36

1 reference

10.1016/J.DRUP.2010.09.002

https://api.crossref.org/works/10.1016/J.DRUP.2010.09.002

20 August 2024

Antifungal pharmacodynamic characteristics of fluconazole and amphotericin B tested against Candida albicans.

38

1 reference

10.1016/J.DRUP.2010.09.002

https://api.crossref.org/works/10.1016/J.DRUP.2010.09.002

20 August 2024

Initial treatment and outcome of Candida glabrata versus Candida albicans bloodstream infection

39

1 reference

10.1016/J.DRUP.2010.09.002

https://api.crossref.org/works/10.1016/J.DRUP.2010.09.002

20 August 2024

Progressive loss of echinocandin activity following prolonged use for treatment of Candida albicans oesophagitis

40

1 reference

10.1016/J.DRUP.2010.09.002

https://api.crossref.org/works/10.1016/J.DRUP.2010.09.002

20 August 2024

Clinical correlates of antifungal macrodilution susceptibility test results for non-AIDS patients with severe Candida infections treated with fluconazole.

41

1 reference

10.1016/J.DRUP.2010.09.002

https://api.crossref.org/works/10.1016/J.DRUP.2010.09.002

20 August 2024

Changes in susceptibility to posaconazole in clinical isolates of Candida albicans

42

1 reference

10.1016/J.DRUP.2010.09.002

https://api.crossref.org/works/10.1016/J.DRUP.2010.09.002

20 August 2024

Distinct patterns of gene expression associated with development of fluconazole resistance in serial candida albicans isolates from human immunodeficiency virus-infected patients with oropharyngeal candidiasis

43

1 reference

10.1016/J.DRUP.2010.09.002

https://api.crossref.org/works/10.1016/J.DRUP.2010.09.002

20 August 2024

Multiple resistant phenotypes of Candida albicans coexist during episodes of oropharyngeal candidiasis in human immunodeficiency virus-infected patients

44

1 reference

10.1016/J.DRUP.2010.09.002

https://api.crossref.org/works/10.1016/J.DRUP.2010.09.002

20 August 2024

Pharmacodynamics of fluconazole in a murine model of systemic candidiasis.

45

1 reference

10.1016/J.DRUP.2010.09.002

https://api.crossref.org/works/10.1016/J.DRUP.2010.09.002

20 August 2024

Molecular basis of resistance to azole antifungals

46

1 reference

10.1016/J.DRUP.2010.09.002

https://api.crossref.org/works/10.1016/J.DRUP.2010.09.002

20 August 2024

Genetic dissection of azole resistance mechanisms in Candida albicans and their validation in a mouse model of disseminated infection

47

1 reference

10.1016/J.DRUP.2010.09.002

https://api.crossref.org/works/10.1016/J.DRUP.2010.09.002

20 August 2024

History of the development of azole derivatives

48

1 reference

10.1016/J.DRUP.2010.09.002

https://api.crossref.org/works/10.1016/J.DRUP.2010.09.002

20 August 2024

Triazole cross-resistance among Candida spp.: case report, occurrence among bloodstream isolates, and implications for antifungal therapy

49

1 reference

10.1016/J.DRUP.2010.09.002

https://api.crossref.org/works/10.1016/J.DRUP.2010.09.002

20 August 2024

Molecular biological characterization of an azole-resistant Candida glabrata isolate

50

1 reference

10.1016/J.DRUP.2010.09.002

https://api.crossref.org/works/10.1016/J.DRUP.2010.09.002

20 August 2024

Development of Fluconazole Resistance inCandida albicansCausing Disseminated Infection in a Patient Undergoing Marrow Transplantation

51

1 reference

10.1016/J.DRUP.2010.09.002

https://api.crossref.org/works/10.1016/J.DRUP.2010.09.002

20 August 2024

Rapid, transient fluconazole resistance in Candida albicans is associated with increased mRNA levels of CDR.

52

1 reference

10.1016/J.DRUP.2010.09.002

https://api.crossref.org/works/10.1016/J.DRUP.2010.09.002

20 August 2024

Identification and Characterization of Four Azole-Resistant erg3 Mutants of Candida albicans

53

1 reference

10.1016/J.DRUP.2010.09.002

https://api.crossref.org/works/10.1016/J.DRUP.2010.09.002

20 August 2024

Susceptibility tests of anaerobic bacteria: statistical and clinical considerations.

54

1 reference

10.1016/J.DRUP.2010.09.002

https://api.crossref.org/works/10.1016/J.DRUP.2010.09.002

20 August 2024

Identification and expression of multidrug transporters responsible for fluconazole resistance in Candida dubliniensis

55

1 reference

10.1016/J.DRUP.2010.09.002

https://api.crossref.org/works/10.1016/J.DRUP.2010.09.002

20 August 2024

Myelofibrosis complicated by infection due to Candida albicans: emergence of resistance to antifungal agents during therapy.

56

1 reference

10.1016/J.DRUP.2010.09.002

https://api.crossref.org/works/10.1016/J.DRUP.2010.09.002

20 August 2024

Multiechinocandin- and multiazole-resistant Candida parapsilosis isolates serially obtained during therapy for prosthetic valve endocarditis

57

1 reference

10.1016/J.DRUP.2010.09.002

https://api.crossref.org/works/10.1016/J.DRUP.2010.09.002

20 August 2024

Isolation and characterization of fluconazole- and amphotericin B-resistant Candida albicans from blood of two patients with leukemia

58

1 reference

10.1016/J.DRUP.2010.09.002

https://api.crossref.org/works/10.1016/J.DRUP.2010.09.002

20 August 2024

Mechanism of fluconazole resistance in Candida krusei

59

1 reference

10.1016/J.DRUP.2010.09.002

https://api.crossref.org/works/10.1016/J.DRUP.2010.09.002

20 August 2024

Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States.

60

1 reference

10.1016/J.DRUP.2010.09.002

https://api.crossref.org/works/10.1016/J.DRUP.2010.09.002

20 August 2024

Rationale for reading fluconazole MICs at 24 hours rather than 48 hours when testing Candida spp. by the CLSI M27-A2 standard method

61

1 reference

10.1016/J.DRUP.2010.09.002

https://api.crossref.org/works/10.1016/J.DRUP.2010.09.002

20 August 2024

Association of fluconazole area under the concentration-time curve/MIC and dose/MIC ratios with mortality in nonneutropenic patients with candidemia

62

1 reference

10.1016/J.DRUP.2010.09.002

https://api.crossref.org/works/10.1016/J.DRUP.2010.09.002

20 August 2024

Clinical significance of azole antifungal drug cross-resistance in Candida glabrata

63

1 reference

10.1016/J.DRUP.2010.09.002

https://api.crossref.org/works/10.1016/J.DRUP.2010.09.002

20 August 2024

Guidelines for treatment of candidiasis

64

1 reference

10.1016/J.DRUP.2010.09.002

https://api.crossref.org/works/10.1016/J.DRUP.2010.09.002

20 August 2024

Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America.

65

1 reference

10.1016/J.DRUP.2010.09.002

https://api.crossref.org/works/10.1016/J.DRUP.2010.09.002

20 August 2024

Adequacy of empirical antifungal therapy and effect on outcome among patients with invasive Candida species infections.

66

1 reference

10.1016/J.DRUP.2010.09.002

https://api.crossref.org/works/10.1016/J.DRUP.2010.09.002

20 August 2024

Prevalence of molecular mechanisms of resistance to azole antifungal agents in Candida albicans strains displaying high-level fluconazole resistance isolated from human immunodeficiency virus-infected patients

67

1 reference

10.1016/J.DRUP.2010.09.002

https://api.crossref.org/works/10.1016/J.DRUP.2010.09.002

20 August 2024

Antifungal resistance in pathogenic fungi

68

1 reference

10.1016/J.DRUP.2010.09.002

https://api.crossref.org/works/10.1016/J.DRUP.2010.09.002

20 August 2024

Molecular mechanisms of fluconazole resistance in Candida dubliniensis isolates from human immunodeficiency virus-infected patients with oropharyngeal candidiasis

69

1 reference

10.1016/J.DRUP.2010.09.002

https://api.crossref.org/works/10.1016/J.DRUP.2010.09.002

20 August 2024

Variations in fluconazole susceptibility and electrophoretic karyotype among oral isolates of Candida albicans from patients with AIDS and oral candidiasis

70

1 reference

10.1016/J.DRUP.2010.09.002

https://api.crossref.org/works/10.1016/J.DRUP.2010.09.002

20 August 2024

Comparison of results of fluconazole disk diffusion testing for Candida species with results from a central reference laboratory in the ARTEMIS global antifungal surveillance program

71

1 reference

10.1016/J.DRUP.2010.09.002

https://api.crossref.org/works/10.1016/J.DRUP.2010.09.002

20 August 2024

Cross-resistance between fluconazole and ravuconazole and the use of fluconazole as a surrogate marker to predict susceptibility and resistance to ravuconazole among 12,796 clinical isolates of Candida spp

72

1 reference

10.1016/J.DRUP.2010.09.002

https://api.crossref.org/works/10.1016/J.DRUP.2010.09.002

20 August 2024

In vitro susceptibilities of clinical isolates of Candida species, Cryptococcus neoformans, and Aspergillus species to itraconazole: global survey of 9,359 isolates tested by clinical and laboratory standards institute broth microdilution methods

73

1 reference

10.1016/J.DRUP.2010.09.002

https://api.crossref.org/works/10.1016/J.DRUP.2010.09.002

20 August 2024

Interpretive breakpoints for fluconazole and Candida revisited: a blueprint for the future of antifungal susceptibility testing

74

1 reference

10.1016/J.DRUP.2010.09.002

https://api.crossref.org/works/10.1016/J.DRUP.2010.09.002

20 August 2024

Use of fluconazole as a surrogate marker to predict susceptibility and resistance to voriconazole among 13,338 clinical isolates of Candida spp. Tested by clinical and laboratory standards institute-recommended broth microdilution methods

75

1 reference

10.1016/J.DRUP.2010.09.002

https://api.crossref.org/works/10.1016/J.DRUP.2010.09.002

20 August 2024

Results from the ARTEMIS DISK Global Antifungal Surveillance study, 1997 to 2005: an 8.5-year analysis of susceptibilities of Candida species and other yeast species to fluconazole and voriconazole determined by CLSI standardized disk diffusion test

77

1 reference

10.1016/J.DRUP.2010.09.002

https://api.crossref.org/works/10.1016/J.DRUP.2010.09.002

20 August 2024

Selection of a surrogate agent (fluconazole or voriconazole) for initial susceptibility testing of posaconazole against Candida spp.: results from a global antifungal surveillance program.

78

1 reference

10.1016/J.DRUP.2010.09.002

https://api.crossref.org/works/10.1016/J.DRUP.2010.09.002

20 August 2024

Validation of 24-hour fluconazole MIC readings versus the CLSI 48-hour broth microdilution reference method: results from a global Candida antifungal surveillance program.

79

1 reference

10.1016/J.DRUP.2010.09.002

https://api.crossref.org/works/10.1016/J.DRUP.2010.09.002

20 August 2024

Wild-type MIC distribution and epidemiological cutoff values for Aspergillus fumigatus and three triazoles as determined by the Clinical and Laboratory Standards Institute broth microdilution methods

80

1 reference

10.1016/J.DRUP.2010.09.002

https://api.crossref.org/works/10.1016/J.DRUP.2010.09.002

20 August 2024

Wild-type MIC distributions and epidemiological cutoff values for the echinocandins and Candida spp.

81

1 reference

10.1016/J.DRUP.2010.09.002

https://api.crossref.org/works/10.1016/J.DRUP.2010.09.002

20 August 2024

Wild-Type MIC Distributions and Epidemiologic Cutoff Values for Fluconazole and Candida: Time for New Clinical Breakpoints?

82

1 reference

10.1016/J.DRUP.2010.09.002

https://api.crossref.org/works/10.1016/J.DRUP.2010.09.002

20 August 2024

Azole resistance of Candida glabrata in a case of recurrent fungemia

83

1 reference

10.1016/J.DRUP.2010.09.002

https://api.crossref.org/works/10.1016/J.DRUP.2010.09.002

20 August 2024

Small colony variants: a pathogenic form of bacteria that facilitates persistent and recurrent infections

84

1 reference

10.1016/J.DRUP.2010.09.002

https://api.crossref.org/works/10.1016/J.DRUP.2010.09.002

20 August 2024

Resistance of Candida albicans to fluconazole during treatment of oropharyngeal candidiasis in a patient with AIDS: documentation by in vitro susceptibility testing and DNA subtype analysis.

85

1 reference

10.1016/J.DRUP.2010.09.002

https://api.crossref.org/works/10.1016/J.DRUP.2010.09.002

20 August 2024

Multiple patterns of resistance to fluconazole in Candida glabrata isolates from a patient with oropharyngeal candidiasis receiving head and neck radiation

86

1 reference

10.1016/J.DRUP.2010.09.002

https://api.crossref.org/works/10.1016/J.DRUP.2010.09.002

20 August 2024

A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute

87

1 reference

10.1016/J.DRUP.2010.09.002

https://api.crossref.org/works/10.1016/J.DRUP.2010.09.002

20 August 2024

Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and candida infections. Subcommittee on Antifungal Susceptibility Te

88

1 reference

10.1016/J.DRUP.2010.09.002

https://api.crossref.org/works/10.1016/J.DRUP.2010.09.002

20 August 2024

Antifungal susceptibility testing: practical aspects and current challenges

89

1 reference

10.1016/J.DRUP.2010.09.002

https://api.crossref.org/works/10.1016/J.DRUP.2010.09.002

20 August 2024

Has antifungal susceptibility testing come of age?

90

1 reference

10.1016/J.DRUP.2010.09.002

https://api.crossref.org/works/10.1016/J.DRUP.2010.09.002

20 August 2024

Statistical analyses of correlation between fluconazole MICs for Candida spp. assessed by standard methods set forth by the European Committee on Antimicrobial Susceptibility Testing (E.Dis. 7.1) and CLSI (M27-A2)

91

1 reference

10.1016/J.DRUP.2010.09.002

https://api.crossref.org/works/10.1016/J.DRUP.2010.09.002

20 August 2024

Correlation of the MIC and dose/MIC ratio of fluconazole to the therapeutic response of patients with mucosal candidiasis and candidemia

92

1 reference

10.1016/J.DRUP.2010.09.002

https://api.crossref.org/works/10.1016/J.DRUP.2010.09.002

20 August 2024

EUCAST definitive document EDef 7.1: method for the determination of broth dilution MICs of antifungal agents for fermentative yeasts

93

1 reference

10.1016/J.DRUP.2010.09.002

https://api.crossref.org/works/10.1016/J.DRUP.2010.09.002

20 August 2024

EUCAST technical note on fluconazole

94

1 reference

10.1016/J.DRUP.2010.09.002

https://api.crossref.org/works/10.1016/J.DRUP.2010.09.002

20 August 2024

In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts

95

1 reference

10.1016/J.DRUP.2010.09.002

https://api.crossref.org/works/10.1016/J.DRUP.2010.09.002

20 August 2024

Candidemia in Norway (1991 to 2003): results from a nationwide study

96

1 reference

10.1016/J.DRUP.2010.09.002

https://api.crossref.org/works/10.1016/J.DRUP.2010.09.002

20 August 2024

Mechanisms of resistance to azole antifungal agents in Candida albicans isolates from AIDS patients involve specific multidrug transporters

97

1 reference

10.1016/J.DRUP.2010.09.002

https://api.crossref.org/works/10.1016/J.DRUP.2010.09.002

20 August 2024

Susceptibilities of Candida albicans multidrug transporter mutants to various antifungal agents and other metabolic inhibitors

98

1 reference

10.1016/J.DRUP.2010.09.002

https://api.crossref.org/works/10.1016/J.DRUP.2010.09.002

20 August 2024

Cloning of Candida albicans genes conferring resistance to azole antifungal agents: characterization of CDR2, a new multidrug ABC transporter gene.

99

1 reference

10.1016/J.DRUP.2010.09.002

https://api.crossref.org/works/10.1016/J.DRUP.2010.09.002

20 August 2024

The ATP binding cassette transporter gene CgCDR1 from Candida glabrata is involved in the resistance of clinical isolates to azole antifungal agents.

100

1 reference

10.1016/J.DRUP.2010.09.002

https://api.crossref.org/works/10.1016/J.DRUP.2010.09.002

20 August 2024

Role of ATP-binding-cassette transporter genes in high-frequency acquisition of resistance to azole antifungals in Candida glabrata.

101

1 reference

10.1016/J.DRUP.2010.09.002

https://api.crossref.org/works/10.1016/J.DRUP.2010.09.002

20 August 2024

Resistance of Candida species to antifungal agents: molecular mechanisms and clinical consequences

102

1 reference

10.1016/J.DRUP.2010.09.002

https://api.crossref.org/works/10.1016/J.DRUP.2010.09.002

20 August 2024

Mechanisms of azole resistance in clinical isolates of Candida glabrata collected during a hospital survey of antifungal resistance

103

1 reference

10.1016/J.DRUP.2010.09.002

https://api.crossref.org/works/10.1016/J.DRUP.2010.09.002

20 August 2024

Staphylococcus aureus small colony variants in prosthetic joint infection.

104

1 reference

10.1016/J.DRUP.2010.09.002

https://api.crossref.org/works/10.1016/J.DRUP.2010.09.002

20 August 2024

Potential confusion regarding the term 'resistance' in epidemiological surveys

106

1 reference

10.1016/J.DRUP.2010.09.002

https://api.crossref.org/works/10.1016/J.DRUP.2010.09.002

20 August 2024

Candidaemia in Europe: epidemiology and resistance

107

1 reference

10.1016/J.DRUP.2010.09.002

https://api.crossref.org/works/10.1016/J.DRUP.2010.09.002

20 August 2024

Statistical characterisation of bacterial wild-type MIC value distributions and the determination of epidemiological cut-off values.

108

1 reference

10.1016/J.DRUP.2010.09.002

https://api.crossref.org/works/10.1016/J.DRUP.2010.09.002

20 August 2024

Setting and revising antibacterial susceptibility breakpoints

109

1 reference

10.1016/J.DRUP.2010.09.002

https://api.crossref.org/works/10.1016/J.DRUP.2010.09.002

20 August 2024

Mechanisms of azole resistance in a clinical isolate of Candida tropicalis

110

1 reference

10.1016/J.DRUP.2010.09.002

https://api.crossref.org/works/10.1016/J.DRUP.2010.09.002

20 August 2024

Staphylococcus aureus small colony variants: difficult to diagnose and difficult to treat

111

1 reference

10.1016/J.DRUP.2010.09.002

https://api.crossref.org/works/10.1016/J.DRUP.2010.09.002

20 August 2024

Increased mRNA levels of ERG16, CDR, and MDR1 correlate with increases in azole resistance in Candida albicans isolates from a patient infected with human immunodeficiency virus

112

1 reference

10.1016/J.DRUP.2010.09.002

https://api.crossref.org/works/10.1016/J.DRUP.2010.09.002

20 August 2024

Clinical, cellular, and molecular factors that contribute to antifungal drug resistance.

114

1 reference

10.1016/J.DRUP.2010.09.002

https://api.crossref.org/works/10.1016/J.DRUP.2010.09.002

20 August 2024

A retrospective Evaluation of fluconazole for the treatment of Candida glabrata fungemia

115

1 reference

10.1016/J.DRUP.2010.09.002

https://api.crossref.org/works/10.1016/J.DRUP.2010.09.002

20 August 2024

Three-dimensional models of wild-type and mutated forms of cytochrome P450 14alpha-sterol demethylases from Aspergillus fumigatus and Candida albicans provide insights into posaconazole binding.

116

1 reference

10.1016/J.DRUP.2010.09.002

https://api.crossref.org/works/10.1016/J.DRUP.2010.09.002

20 August 2024

Identifiers

10.1016/J.DRUP.2010.09.002

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33738435&oldid=2232196967"